News|Articles|August 31, 2021

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of August 31, 2021

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

How widespread is the Delta variant (B.1.617.2) in the US?

According to early estimates from the Centers for Disease Control and Prevention (CDC), as of August 31, 2021, the SARS-CoV-2 Delta variant made up 99.1% of COVID-19 cases in the United States.

The CDC estimates as of August 31, 2021, the 5 states with the highest unweighted proportion of new cases attributed to the SARS-CoV-2 Delta variant are:

1. District of Columbia: 98.9%
2. Vermont: 98.7%
3. Kansas: 97.8%
4. Pennsylvania: 97.8%
5. Virginia: 97.4%

How many people in the US have been vaccinated against COVID-19?

According to the CDC as of today, August 31, 2021, at 2:55 PM, EDT:

• 61.8% of total US population has received at least 1 dose
• 52.4% of total US population is fully vaccinated

The 5 states with the highest percentage of population fully vaccinated are:

1. Vermont: 67.9%
2. Connecticut: 66%
3. Massachusetts: 66%
4. Maine: 65.8%
5. Rhode Island: 64.7%

How many cases of COVID-19 have been confirmed in the US?

According to the Johns Hopkins COVID-19 interactive map, as of today, August 31, 2021 at 2:21 PM, EDT, there have been:

• 39 115 924 confirmed cases and
• 639 390 deaths

The 5 states with the highest total confirmed cases are:

1. California: 4 352 397
2. Texas: 3 594 335
3. Florida: 3 223 249
4. New York: 2 278 590
5. Illinois: 1 518 071

Deaths: California has the highest number of deaths due to COVID-19 with 65 828 reported fatalities, followed by Texas with 56 837 and New York with 54 254.

How many cases of COVID-19 have been confirmed globally?

Globally, there have been 217 460 053 confirmed cases, 4 515 403 deaths, and 5 273 497 378 vaccine doses administered.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Latest CME

Multimedia

Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments

Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Anil K. Agarwal, MD; Nissreen Elfadawy, MD, MSc, FASN

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

COVID-19 Updates: Delta Variant, US Vaccinations, & Global Data as of August 31, 2021

How widespread is the Delta variant (B.1.617.2) in the US?

How many people in the US have been vaccinated against COVID-19?

How many cases of COVID-19 have been confirmed in the US?

How many cases of COVID-19 have been confirmed globally?

Newsletter

Related Content

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Menopause: A Constellation of Syndromes Across 13 Body Systems

Marla Shapiro, CM‎, MDCM, on Recognizing Early Perimenopause: Sleep, Mood, and Other Missed Clues

Menopause Education Lags in Residency Training Across Primary Care Specialties

Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease

Latest CME

Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments

Expert Illustrations and Commentaries™: The Role of the Paracellular Pathway in the Management of Hyperphosphatemia in CKD

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Breast Cancer Symposia in San Antonio

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Real Psychiatry 2026

19th Annual New York GU Cancers Congress™

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

43rd Annual Miami Breast Cancer Conference®

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

Homing in on the Role of PSMA in Prostate Cancer – Harnessing the Power of Precision Medicine Through Imaging and Therapy to Individualize Treatment Plans

2nd Annual Hawaii Cancer Conference

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis

Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors

Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Settings

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

Raising Our Game in the Management of Hyperlipidemia: New Targets, New Tactics

Medical Crossfire®: New Horizons in Hemolytic Anemias – How I Diagnose & Treat Based on Individual Patient and Disease Characteristics

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure